Ssangyong shares "swallowed" gold bao pharmaceutical core assets why not mention

This reporter Xu Guming Ssangyong shares issued after the takeover plan stock price ups and downs. February 24, Ssangyong shares (300108) trading, the stock price reached a record high, 18.64 yuan, the previous trading day February 21, the shares fell 7.04%. November 5, 2013 before the suspension of the trading day of the stock price is 7.14 yuan, February 7 after the card after 8 consecutive trading. Stock prices behind the ups and downs, is the market for the purchase plan as the Campbell Pharmaceutical "core Outlook Assets"-"Le Tatsu non-Chinese medicine anti-virus drug production base" No information on the question. And in the recent interview with the China Economic Times reporter, Ssangyong shares and the gold Bao pharmaceutical related to the responsible person actually gave a diametrically opposite argument. Disappearing "project" This February 7, the 3-month suspension of Ssangyong shares disclosed the asset restructuring program, the company to 1.08 billion yuan to "swallow" volume than its own twice times the gold Bao pharmaceutical industry, the main business transition to chemical-pharmaceutical "dual habitat." The reorganization plan said, Ssangyong shares proposed "fixed increase + cash" way total 1.08 billion yuan to buy gold Bao pharmaceutical 100% of the shares. By the end of 2013, the total assets of Jinbao pharmaceutical industry 1,099,085,600 yuan, net assets of 654.4341 million yuan. China Economic Times reporter learned that, as a well-known local pharmaceutical companies, in the foreign investment to highlight the potential will be highlighted in its IPO project "Le Tatsu non-Traditional Chinese medicine anti-virus drug production base" of the golden Treasure pharmaceutical industry in the Double Dragon shares in the plan to increase the acquisition of the plans have no news. Jinbao pharmaceutical industry has been the local support of the quasi-listed star enterprises, "Le Tatsu non-Chinese medicine anti-virus drug production base" project is its future profitable core assets. China Meihekou official website shows, August 6, 2011, Haitong Givo and Jinbao Pharmaceutical Industry held a strategic investment cooperation signing ceremony said, "the company is going to build the listed investment project ' Le Tatsu non-Chinese medicine anti-virus drug production base ' total investments of 260 million yuan, is expected to produce a production value of more than 1 billion yuan, The total profits and taxes exceed 380 million yuan. The project is now under construction. "Meihekou 2012 government work report also said that the Jinbao pharmaceutical investment of 1 billion yuan of Chinese Medicine anti-virus project, investment 500 million yuan of anti-HIV products drug projects have been built." At present, Ssangyong bought all the assets of the Jinbao pharmaceutical industry. Why the Jinbao Pharmaceutical project to build the listing of "Le Tatsu non-Chinese medicine anti-virus drug production base" project in the reorganization plan did not disclose? In this respect, Ssangyong Securities department Head of the China Economic Times reporter said, "Le Tatsu non-Chinese medicine anti-virus drug production base is not included in this reorganization." "Ssangyong shares on its investor interactive platform also said," The ' investment Project ' is not included in the reorganization. "In stark contrast," said the head of the company, who declined to be named, "Ssangyong is 100% of the acquisition of gold Bao pharmaceutical industry, le Tatsu non-Chinese medicine anti-virus drug production base project must include." "When the reporter mentions Ssangyong Stock Securities Affairs Department" does not contain "in the plan, the official said," We also at noon and Ssangyong shares dong aTo discuss things, the final message must be issued by the Secretary for Foreign Affairs. "Suspected violation of the listing of the shell is worth noting, Ssangyong stock restructuring plan suspected to be listed by the shell, and regulatory departments" gem companies may not borrow shell listing "provisions. The reason for this, Jinbao pharmaceutical assets than Ssangyong shares. According to the plan, the Jinbao pharmaceutical industry at the end of 2013 total assets and net Asset account value of 1.099 billion yuan, 654 million yuan, 2013 to achieve revenue of 368 million yuan, are more than Ssangyong shares related data 200%. "According to the listed companies constitute backdoor provisions, the total assets of the acquirer of the acquirer listed companies to change the control of the total amount of assets in the previous fiscal year in the proportion of more than 100%, is a backdoor listing." But Ssangyong shares that the holding power has not changed, denying its buying shell behavior. "The head of an investment company in Beijing said to the China Economic Times reporter. VCs or will become "nouveau riche" in addition, VCs will be the "nouveau riche" after the reorganization. It is reported that the Jinbao pharmaceutical industry its predecessor Jinbao Limited was founded in May 27, 1998, before and after 6 equity transfer 4 increase in capital, the current shareholder 62, including Sun June and other 52 natural persons and the Chinese Medicine Fund 10 corporate shareholders (including 9 PE Agency/Partnership Fund). According to the financial report of the major Project laboratory data statistics, Jinbao pharmaceutical real control person sun June, such as 62 asset sellers invested capital Bao pharmaceutical stock costs amounted to about 371 million yuan, according to the February 20 closing price calculation, its book investment income of about 1.86 billion yuan, the average investment returns 5 times times. Among them, Sun June couple book investment income 728 million yuan, investment returns 12 times times. It is noteworthy that the established in June 26, 2012, the Chinese Medicine fund, behind the China Pharmaceutical group, Fosun Pharmaceutical and other large enterprises, in December 2012 to enter the Gold Po Pharmaceutical industry, book investment income of about 325 million yuan. Haitong Kaiyuan shares 37.5% of the Jilin Modern Agricultural Fund, is currently earning about 219 million yuan in book investment.